期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

左西孟旦心脏围手术期应用研究进展 被引量：4

Application of Levosimendan in Perioperative Period of Cardiac Surgery
下载PDF
导出
摘要 左西孟旦为钙离子增敏剂,通过肌钙蛋白C对钙离子的增敏作用来提高心肌收缩力,且不增加细胞内环磷腺苷和细胞内钙离子浓度。左西孟旦具有正性肌力作用但不提高细胞内钙离子浓度和心肌耗氧量,可降低危重症患者的死亡率,在心脏围手术期有应用价值。该文对左西孟旦的药理作用、药代动力学及在心衰患者围手术期应用进行综述,为其进一步临床使用提供参考。 Levosimendan is a kind of calcium sensitizers. It imProves myocardial contractility by sensitization of troPonin C to calcium without increasing intracellular cAMP or intracellular calcium concentration. Levosimendan has a Positive inotroPic effect without increas-ing the intracellular calcium ion concentration and myocardial oxygen consumPtion, and can reduce mortality in critically ill Patients, has aPPlication value in the PerioPerative cardiac surgery Period. This review summarize the Pharmacology and Pharmacokinetics of levosi-mendan and aPPlication of levosimendan in Patients with heart failure in PerioPerative Period, in order to Provide reference for its further clinical aPPlication.
作者 沈如华 严中亚
机构地区 安徽医科大学附属省立医院心脏外科
出处 《中国药业》 CAS 2015年第17期132-135,共4页 China Pharmaceuticals
关键词 左心孟旦 心力衰竭 心脏手术 进展 levosimendan heart failure cardiac surgery progress
分类号 R969 [医药卫生—药理学] R972.1 [医药卫生—药品]
  • 相关文献

参考文献39

  • 1Figgit DP, Gilles PS, Goa KL. Le,eosimendan[J] . Drugs, 2001,61 (5): 613 -627.
  • 2Raja SG, Rayen BS. Levosimendan in cardiac surgery: current best avail- able evidence [ J ]. Ann Thorac Surg, 2006,81 (4) : 1 536 - l 546.
  • 3Tritapepe L, De Santis V, Vitale D, et al. Preconditioning effects of levosi- mendan in coronary artery bypass grafting-A-pilot study[J]. Br J Anaesth, 2006,96 (6) : 694 - 700.
  • 4Kivikko M, Antila S, Eha J, et al. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion inpatients with severe heart failure[J]. J Clin Pharmacol,2002, 42(1): 43 -51.
  • 5Rognoni A, Lupi A, Lazzero M, et al. Levosimendan: from basic science to clinical trials[J]. Recent PatCardiovasc Drug Discov,2011,6(1 ): 9 - 15.
  • 6Bleumink GS, Knetsch AM, Sturkenboom MC. Quantifying the heart failure epidemic: Prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study[J]. Eur I-Ieart J,2004,25(18): 1614 - l 619.
  • 7Antila S, Sundberg S, Lehtonen LA. Clinical pharmacology of levosimen- dan [ J ]. Clinical Pharmacokinetics, 2007,46 (7) : 535 - 552.
  • 8Innes CA,Wagstaff AJ. Levosimendan: A review of its use in the manage- ment of acute decompensated heart failure [ J ]. Drugs, 2003,63 (23): 2 651 -2 671.
  • 9Slawky MT, Colucci WS, Gottlieb SS. Acute hemodynamic and clinical ef- fects of levosimendan in patients with severe heart failure [J ]. Circulation, 2000,102 (18) : 2 222 - 2 227.
  • 10Nieminen MS, Akkila J, I-Iasenfuss G. Hemodynamic and neurohumoral effects of continous infusion of |evosimendan in patientswith congestive heart failure[J]. J Am Coll Cardiot,2000,36(6): 1 903 - 1 912.

同被引文献45

  • 1Tarkia M,Stark C, Haavisto M,et al. Effect of levosimen- dan therapy on myocardial infarct size and left ventricular function after acute coronary occlusion[J]. Heart,2016, 102 (6) :465-471.
  • 2Kersten JR, Montgomery MW,Pagel PS, et al. Levosimen- dan,a new positive inotropic drug,decreases myocardial infarct size via activation of KATP channels[J]. Auesth Analg, 2000,90( 1 ) : 5-11.
  • 3Kaheinen P,Pollesello p,Levijoki J,et al. Effects of levosi- mendan and milrinone on oxygen consumption in isolated guinea-pig heart[J]. J Cardiovase Pharmacol,2004,43 (4) : 555-561.
  • 4Orstavik O,Ata SH,Riise J, Inhibition of phosphodi- esterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart[J]. Br J Pharmacol, 2014,171(23) :5169-5181.
  • 5Yilmaz MB, Grossini E,Silva Cardoso JC, et al. Renal Effects of Levosimendan:A Consensus Report[J]. Cardio- vasc Drugs Ther, 2013,27 (6) : 581-590.
  • 6Bragadottir G,Redfors B, Ricksten SE. Effects of levosi- mendan on renal blood flow, glomerular filtration rate, re- nal oxygen consumption and oxygenation after cardiac surgery:A randomized controlled study[J]. Crit Care Med, 2013,41 (10) : 2328-2335.
  • 7Torrado H, Lopez-Delgado JC, Farrero E et al. Five-year mortality in cardiac surgery patients with low cardiac output syndrome treated with levosimendan:Prognostie e- valuation of NT-proBNP and C-reactive protein[J]. Min- erva Cardioangiol, 2016,64(2) : 101-103.
  • 8Antila S,Pesonen U, Lehtonen L,et al. Pharmacokinetics of levosimendan and its active metabolite 0R-1896 in rapid and slow acetylators[J]. Eur J Pharm Sci, 2004,23 (3) :213-222.
  • 9Jaakko P,Sampo K, Angela R, et al. Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepmic impairment[J]. J Clin Pharmacol, 2008,48 (4) :445-454.
  • 10郭攀,王平,孙漾丽,等. 左西孟旦治疗急性心力衰竭62例疗效观察[J]. 中华全科医学,2013,11(5):680-1.

引证文献4

二级引证文献14

中国药业
2015年 第17期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部